Redet mit mir - bitte!!! Axonyx, Inc., US05461R1014... - 500 Beiträge pro Seite

[armerstudent]

Was haltet Ihr von folgender Aktie...


Axonyx, Inc., US05461R1014

http://www.axonyx.com

http://www.axonyx.com/pipeline/index.html

http://finance.yahoo.com/q?s=AXYX&d=b

http://www.knobias.com/individual/public/quote.htm?ticker=AX…

http://www.wallstreet-online.de/market/charts/chartpic.php?&…

[BrauchGeld]

Hi

Bin mit einer kleinen Position dabei.Ist halt ne riskante Aktie.Aber sollte das Alzheimer medikament zugelassen werden dürften mindestens 800 % drin sein.Aber meiner meinung nach ist das Risiko etwas höher als die Chancen.Hab das vor kurzem mit Alteon erlebt.

Naja no risk no fun.

Gruss
B.M.

[cybomaniac]

solltest du in axonyx investiert sein, ist das definitiv venturecapital.
aber ein medikament in phase 3 lässt doch hoffen.
heute auch wieder im plus trotz schwacher nasdaq.
meine meinung: durchaus ein risiko wert- 3% vom portfolio
mittelfristig

[puhvogel]

Ich kann mich meinen Vorgängern nur anschliessen. Das ein Medikament in Phase 3 gekommen ist, ist ein positiver Fakt. Dennoch: Ein Neuro-Medikament zugelassen zu bekommen ist das schwierigste Unterfangen überhaupt.

Mit 87 Millionen Dollar ist die Firma noch vergleichsweise billig, das heißt implizit aber auch, dass der Markt ein wenig skeptisch über die Erfolgschancen ist.

[t.1]

@puhvogel

die frage die ich mir stelle,ist ob nach einer nichtzulassung oder fehlschlag genug geld da ist um weiterzumachen. 8,00 millionen $ ist nichtgerade üppig.

aber 3000 € mit der chance auf verdreifachung.....ist eine überlegung wert.

grüße t.1

[kurttilly]

Hallo ihr Axonyxsten!!


was ist los in USA mit Axonyx ???




WKN: 928329 Ticker: XYX Sektor: n.a.
ISIN: US05461R1014 Branche: n.a. Land: USA


Börse Währung Datum Uhrzeit Akt.
Kurs Veränderung zum Vortag Tages 52-Wochen
abs. in % Tief Hoch Tief Hoch
Nasdaq NM USD 11.09.2003 21:23 3,88 +0,47 +13,78% 3,21 4,15 0,53 4,19





hat jemand Neuigkeiten?


mfg kurttilly

[armerstudent]

Das interessiert mich allerdings auch - 1,5 Mio. gehandelte Aktien, 3-Monatsdurchschnitt liegt bei 260.000!

[armerstudent]

Last Trade: 3.93

Change: 0.55 (16.27%)

Avg Vol (3m): 258,954

Market Cap: 101.29M

Volume: 1,760,787

[BrauchGeld]

Hi

#7

Ich denke der Anstieg hat was mit der Life Science Konferenz zu tun.Da werden die Fortschritte mitgeteilt.
Gruss
B.M.

[armerstudent]

#9

Gibt es von bzw. zu dieser Konferenz eine Internetseite?
Ich habe bei google.de nichts gefunden!

[armerstudent]

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Press Release Source: Axonyx Inc.


Axonyx Announces $25 Million Private Placement of Common Stock and Warrants
Friday September 12, 9:35 am ET


NEW YORK--(BUSINESS WIRE)--Sept. 12, 2003--Axonyx Inc. (NASDAQ:AXYX - News) announced today that the Company has entered into definitive agreements with new and existing institutional investors relating to a private placement of $25 million of securities through the sale of 7,476,636 shares of common stock at $3.25 per share. These agreements also involve the acquisition by the investor group of five-year warrants to purchase an additional 5,607,471 shares of the Company`s stock at an exercise price of $3.50 per share. The Company will file a registration statement with the SEC for the resale of common stock within 30 days.
Rodman & Renshaw Inc. and Punk Ziegel & Co. were placement agents for this transaction. In addition, Punk Ziegel & Co. acted as financial advisor to Axonyx.

Axonyx plans to use the net proceeds of this financing transaction to support the Company`s strategic business objectives that include the continued clinical development of Phenserine, the Company`s lead product to treat Alzheimer`s disease (AD).

"This successful financing secures the ability of Axonyx to initiate a second phase III clinical trial with Phenserine," stated Marvin S. Hausman, M.D., Chairman/CEO of Axonyx, Inc. "A phase III clinical trial of Phenserine is already underway in Europe and we are pleased with the progress of the study to date."

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer`s disease, human memory disorders and prion-based illnesses such as Mad Cow disease.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx`s annual report on Form 10-K. Axonyx cannot assure that the Phase III clinical trials, or others, if any, with Phenserine will prove successful, that the safety and efficacy profile of Phenserine exhibited in the previous small Phase II trial will remain the same in the Phase III clinical trials, or future clinical trials, if any, that Phenserine will be able to slow the progression of Alzheimer`s disease, that the efficacy results of the Phase III trial will prove pivotal, that Axonyx will obtain the necessary financing to complete the Phase III Phenserine trials, that the Company`s development work on Phenserine will support an NDA filing, that the results of the Phase III trials will allow Phenserine to be approved by the FDA, that the FDA will grant marketing approval for Phenserine, that if Phenserine is approved by the FDA, it will prove competitive in the market, and that Axonyx will obtain licensing or corporate partnership agreements that will enable acceleration of the development of and optimize marketing opportunities for, Phenserine, or that Axonyx will be able to advance any other potential memory enhancing compound toward IND status. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



--------------------------------------------------------------------------------
Contact:
Axonyx Inc., New York
Victoria Trahan, 212-645-7704
Fax: [phone]
www.axonyx.com
or
Wolfe Axelrod Weinberger Assoc. LLC
Donald C. Weinberger
Andria Pilo (Media)
212-370-4500
Fax: [phone]
[e-mail]



--------------------------------------------------------------------------------
Source: Axonyx Inc.

[armerstudent]

Axonyx Names S. Colin Neill as Chief Financial Officer
Monday September 15, 2:47 pm ET

NEW YORK--(BUSINESS WIRE)--Sept. 15, 2003--Axonyx Inc. (NASDAQ: AXYX - News) is
pleased to announce the appointment of S. Colin Neill as Chief Financial Officer and Treasurer
effective September 15, 2003.

Mr. Neill served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer of
ClinTrials Research Inc., a $100 million publicly traded global contract research organization in
the drug development business, from 1998 to its successful sale in 2001. Since that sale, Mr.
Neill has served as an independent consultant assisting small start-up and development stage
companies raise capital.

Mr. Neill`s career experience has included that of Acting Vice President Finance and Chief
Financial Officer of Pharmos Corporation, a biopharmaceutical company in the business of
developing novel drug technologies. Earlier experience was gained as Vice President Finance
and Chief Financial Officer of BTR Inc., a $3.5 billion US subsidiary of BTR plc, a British
diversified manufacturing company, and Vice President Financial Services of The BOC Group
Inc., a $2.5 billion British owned industrial gas company with substantial operations in the
health care field. Mr. Neill has served four years with American Express Travel Related
Services, firstly as chief internal auditor for worldwide operations and then as head of business
planning and financial analysis. Mr. Neill began his career in public accounting with Arthur
Andersen LLP in Ireland and later with Price Waterhouse LLP as a senior manager in New York
City. He also served with Price Waterhouse for two years in Paris, France.

Mr. Neill graduated from Trinity College, Dublin with a first class honors degree in
Business/Economics and he holds a masters degree in Accounting and Finance from the
London School of Economics. He is both a Certified Public Accountant (CPA) in New York
State and a Chartered Accountant (FCA) in Ireland.

Mr. Neill has served as a member of the Board of Directors of the Association of Chartered
Accountants in the US, a professional not-for-profit organization representing the interests of
some 4,000 US-based chartered accountants from around the world.

"We are very excited to have Mr. Neill on board. He joins us at a critical point in Axonyx`s
development with an exceptional background and leadership experience. His broad based
experience in drug development and strategic planning will prove invaluable as Axonyx grows,"
commented Marvin S. Hausman, M.D., President, CEO and Chairman.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and
development of proprietary pharmaceutical compounds and new technologies useful in the
diagnosis and treatment of Alzheimer`s disease, human memory disorders and prion-based
illnesses such as Mad Cow disease.

This press release may contain forward-looking statements or predictions. These statements
represent our judgment to date, and are subject to risks and uncertainties that could materially
affect the Company including those risks and uncertainties described in the documents Axonyx
files from time to time with the SEC, specifically Axonyx`s annual report on Form 10-K. Axonyx
undertakes no obligation to publicly release the result of any revisions to such forward-looking
statements that may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

Contact:

Axonyx Inc., New York
Victoria Trahan, [phone]
Fax: [phone]
www.axonyx.com
or
Wolfe Axelrod Weinberger Assoc. LLC
Donald C. Weinberger
Andria Pilo (Media)
[phone]; [phone] (Fax)
[e-mail]



Source: Axonyx

[boerse-bild]

Heute könnte die 4$-Marke genommen werden und dann schießen auch die Umsätze wieder in die Höhe!
Heute plus 15 % !!!

[boerse-bild]

Das sieht gut aus, das werden mindestens 15 % - egal ob die Nasdaq steigt oder nicht!!!

[boerse-bild]

http://www.wallstreet-online.de/market/charts/chartpic.php?u…

http://www.wallstreet-online.de/market/charts/chartpic.php?u…

Wenn sie heute deutlich über der 4$-Marke schließt, dann wird sie innerhalb kürzester Zeit (das ist dann eine Frage von Stunden!) auf ihr All-Time High schießen - und dann nix wie raus!!!

[boerse-bild]

Heute macht sie 30 % - bei gewltigen Umsätzen!!!

Vorbörslich: Fast 7 % im Plus

http://finance.yahoo.com/q?s=AXYX&d=b

[armerstudent]

Axonyx Expands Ongoing Phenserine Clinical Program
Thursday September 18, 8:32 am ET


NEW YORK--(BUSINESS WIRE)--Sept. 18, 2003--Axonyx Inc. (NASDAQ:AXYX - News) today announced that it intends to provide Alzheimer`s disease (AD) patients in the ongoing Phase IIB and Phase III clinical trials the opportunity to receive Phenserine treatment in a formal open label six-month extension study. Phenserine is a dual action acetylcholinesterase and beta amyloid precursor protein (B-APP) inhibitor currently in clinical development for the treatment of mild-to-moderate Alzheimer`s disease.
All patients that have completed the previously announced and ongoing 75 patient Phase IIB and the 375 patient Phase III clinical trials will be given the opportunity to receive six months of Phenserine treatment in an open-label extension study. Patients previously treated with Phenserine can receive Phenserine for an additional six months, while patients previously treated with placebo can receive their initial six-month treatment period with Phenserine. The Phase IIB double-blind placebo-controlled clinical study is designed to examine the effects following six months of Phenserine treatment on the levels of B-APP and amyloid beta (A-B) in the spinal fluid and plasma of mild-to-moderate AD patients. The Phase III double-blind placebo-controlled study will provide efficacy and safety data in mild-to-moderate AD patients following six months of Phenserine treatment.

Open label extension studies are often conducted to generate safety and efficacy data from patients on long-term treatment. Such data could be valuable in order to potentially meet long-term drug exposure requirements that support the safety and chronic use of a drug, set by Regulatory Authorities.

"We feel that it is appropriate to expand the ongoing program to generate these additional long term data following our successful recently completed financing", stated Gosse B. Bruinsma, M.D., Chief Operating Officer, Axonyx Inc. "The ongoing clinical studies are progressing and we expect that the first patients could choose to enter this open label study at the conclusion of their clinical trial protocol."

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer`s disease, human memory disorders and prion-based illnesses such as Mad Cow disease.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx`s annual report on Form 10-K. Axonyx cannot assure that the Phase IIB and/or the Phase III clinical trial, or others, if any, with Phenserine will prove successful, that the safety and efficacy profile of Phenserine exhibited in the previous small Phase II trial will remain the same in the Phase IIB and Phase III clinical trials, or future clinical trials, if any, that the preclinical results related to the regulation of beta-APP will be substantiated by the Phenserine Phase IIB clinical trial and that Phenserine will be able to slow the progression of Alzheimer`s disease, that the Phase IIB clinical trial data will differentiate Phenserine from the currently marketed drugs, that the efficacy results of the Phase III trial will prove pivotal, that the efficacy data from the Phase IIB clinical trial will be able to be used in the Phase III trial efficacy data, that Axonyx will obtain the necessary financing to complete the Phase III Phenserine trials, that the Company`s development work on Phenserine will support an NDA filing, that the results of the Phase III trials will allow Phenserine to be approved by the FDA, that the FDA will grant marketing approval for Phenserine, that if Phenserine is approved by the FDA, it will prove competitive in the market, and that Axonyx will obtain licensing or corporate partnership agreements that will enable acceleration of the development of and optimize marketing opportunities for, Phenserine, or that Axonyx will be able to advance any other potential memory enhancing compound toward IND status. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



--------------------------------------------------------------------------------
Contact:
Axonyx Inc., New York
Victoria Trahan, 212-645-7704
Fax: [phone]
www.axonyx.com
or
Wolfe Axelrod Weinberger Assoc. LLC
Donald C. Weinberger
Andria Pilo
212-370-4500
Fax: [phone]
[e-mail]



--------------------------------------------------------------------------------
Source: Axonyx Inc.